Abstract
Testosterone therapy (TTh) is a well-established and safe treatment for men with testosterone deficiency. Historically, great caution has been used in the use of testosterone in men with prostate cancer (PCa) given the pioneering work by Huggins and Hodges showing castration decreased serum acid phosphatase in men with metastatic PCa. For the past several decades new theories including the saturation model have gained traction and as a result the treatment of testosterone deficiency in men with PCa has been transformed. In men treated for localized PCa with prostatectomy a growing body of evidence exists supporting its safety and efficacy in these men. In addition, it has been suggested that TTh may decrease biochemical recurrence. The data are more limited in men treated with radiation and there are no studies currently with a control group. Overall, the body of literature continues to grow suggesting the safety of TTh in well-selected men treated for localized PCa.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
